Mirum Pharmaceuticals
(NASDAQ) MIRM
Mirum Pharmaceuticals Financials at a Glance
Market Cap
$5.64B
Revenue (TTM)
$569.61M
Net Income (TTM)
-$798.84M
EPS (TTM)
-$13.60
P/E Ratio
-6.80
Dividend
$0.00
Beta (Volatility)
0.75 (Low)
Dividend
$0.00
Beta (Volatility)
0.75 (Low)
Price
$92.51
Volume
389
Open
$92.10
Price
$92.51
Volume
389
Open
$92.10
Previous Close
$92.49
Daily Range
$91.92 - $95.25
52-Week Range
$45.17 - $114.99
Estimated Earnings Date
Jul 30, 2026
Dividend
$0.00
Beta (Volatility)
0.75 (Low)
Price
$92.51
Volume
389
Open
$92.10
Previous Close
$92.49
Daily Range
$91.92 - $95.25
52-Week Range
$45.17 - $114.99
Estimated Earnings Date
Jul 30, 2026
MIRM News
MIRM: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Mirum Pharmaceuticals
Industry
Biotechnology
Sector
Health CareEmployees
372
CEO
Christopher Peetz, MBA
Website
www.mirumpharma.comHeadquarters
Foster City, CA 94404, US
MIRM Financials
Key Financial Metrics (TTM)
Gross Margin
81%
Operating Margin
-12%
Net Income Margin
-1%
Return on Equity
-336%
Return on Capital
-11%
Return on Assets
-90%
Earnings Yield
-14.71%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$5.64B
Shares Outstanding
60.98M
Volume
389
Avg. Volume
980.05K
Financials (TTM)
Gross Profit
$420.73M
Operating Income
-$22.14M
EBITDA
$17.21M
Operating Cash Flow
$55.83M
Capital Expenditure
-$954.00K
Free Cash Flow
$54.87M
Cash & ST Invst.
$383.33M
Total Debt
$319.45M
Mirum Pharmaceuticals Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$159.88M
+43.3%
Gross Profit
$131.00M
+47.9%
Gross Margin
81.94%
N/A
Market Cap
$5.64B
N/A
Market Cap/Employee
$16.89M
N/A
Employees
334
N/A
Net Income
-$790.16M
-5283.6%
EBITDA
-$56.29M
-1307.2%
Quarterly Fundamentals
Net Cash
$62.48M
+258.2%
Accounts Receivable
$133.11M
+38.9%
Inventory
$25.52M
+13.8%
Long Term Debt
$321.43M
+1.9%
Short Term Debt
$2.35M
+43.1%
Return on Assets
-89.67%
N/A
Return on Invested Capital
-11.34%
N/A
Free Cash Flow
-$229.43M
-11359.9%
Operating Cash Flow
-$228.76M
-11565.6%